![Boston_H_color[33632]_edited.png](https://static.wixstatic.com/media/e60c5c_0b72738a80554196840094a8e387c5ed~mv2.png/v1/fill/w_338,h_77,al_c,q_85,usm_0.66_1.00_0.01,enc_avif,quality_auto/Boston_H_color%5B33632%5D_edited.png)
The Only CDK4 & CDK6 Inhibitor Approved Across HR+, HER2 - MBC
Wed, Dec 12
|Joey's Bar & Grill
Verzenio is indicated for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2- negative (HER2-) advanced or metastatic breast cancer (MBC)
Time & Location
Dec 12, 2018, 5:30 PM
Joey's Bar & Grill, 344 Chandler St, Worcester, MA 01602, USA
Guests
About The Event
Speaker:
Blanca Ledezema, APN, APNP, MN, MS, NP
UCLA Hematology Oncology Santa Monica, CA
Description:
This program will present efficacy and safety data for Verzenio, a CDK4 + CDK6 inhibitor approved in comibination with fluvestrant, in combination with an Al, and as a single age for HR+, HER2- advanced or MMBC. Information about mechanism of action and dosing will also be presented.
Program Objectives:
~Discuss the unmet needs for women with HR+, HER2- MBC
~Examine the efficacy and safety profile of Verzenio
~Review practical considerations for the use of Verzenio
RSVP to Aimee Ferry at Ferry_aimee_R@lilly.com or by phone at 603-475-4602.